Bladder Cancer Weekly

July 20, 2026

Videos

Peer-to-Peer Clinical Conversations

Perioperative Outcomes After Radical Surgery Following EV Pembrolizumab in Urothelial Carcinoma - Daniel Roberson

Daniel Roberson discusses perioperative outcomes after enfortumab vedotin plus pembrolizumab, drawing on patients who underwent radical cystectomy or radical nephroureterectomy following this first-line combination.

View

Randomized Trial of Blue Light Versus White Light TURBT with Urinary Tumor DNA Testing - Armine Smith & Meghan McNamara

Armine Smith

Meghan McNamara and Armine Smith describe a randomized study combining blue-light TURBT with UroAmp urinary tumor DNA testing.

View

Beyond the Abstracts

A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity - Beyond the Abstract

Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial - Beyond the Abstract

Conference Coverage

ASCO 2026: Initial Results from EXCEED, a Phase 1 Study of LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma

ASCO 2026: Assessing Responses to UGN-102 Across EORTC Recurrence Score Groups in Patients with Recurrent Low Grade Intermediate Risk NMIBC (ENVISION Trial)

ASCO 2026: Feasibility and Safety Results from RAD-IO: A Multi-Stage Trial of Durvalumab with Chemoradiotherapy with 5-FU and Mitomycin C in Pts with MIBC

AUA 2026: Alvimopan in Patients Undergoing Radical Cystectomy and Urinary Diversion on a Standardized Enhanced Recovery After Surgery Protocol: A Randomized, Double-Blind, Placebo-Controlled Trial

SES AUA 2026: Differences in Restaging TURBT Pathology Outcomes Based on Index TURBT Performed by an SUO Fellowship Trained or Non-SUO Trained Urologist  

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.

Comprehensive clinical and genomic analysis of early onset cancer of the bladder and upper urinary tract.

Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC).

Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes.

Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update.

Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.

Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.

Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.

Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study.

Assessing the concordance between ChatGPT-4 and EAU guidelines indications in bladder cancer management: a real-world study.

Immunohistochemistry-Based Molecular Subtyping in Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy.

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Factors Influencing Adherence to Intravesical Instillation Therapies for Non-Muscle-Invasive Bladder Cancer: A Scoping Review Protocol - Beyond the Abstract

Pathological Assessment of Morcellated Tissue after ERBT: Insights from a Two-Round Delphi Survey - Beyond the Abstract

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract

AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login